Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cellectricon Launches Neurotoxicity Testing Services | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cellectricon Launches Neurotoxicity Testing Services

New services enable early assessment of compound safety and neurotoxic risk in drug discovery.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Cellectricon Neurotoxicity Testing Services

Cellectricon, a neuroscience drug discovery services provider, launched its new Neurotoxicity Testing Services, expanding its discovery platform to support the early safety assessment of drug candidates. With growing interest and feedback from the neuroscience community, the new service aims to enable drug developers to detect potential neurotoxic effects sooner, helping to reduce risk, save time, and improve confidence in candidate selection.

The new testing services draw on Cellectricon’s neuroscience expertise and portfolio of validated in vitro models. Assays integrate optical electrophysiology, high-content imaging, and microfluidic systems. The result is an ability to evaluate a broad range of acute and chronic neurotoxicity endpoints, including neuronal excitability, neurite outgrowth, metabolic activity, cytokine release, and cellular phenotype. 

“In recent years, we’ve seen growing demand for early-stage neurotoxicity testing—particularly from teams developing oligonucleotide-based drugs, who often face challenges in obtaining reliable, accurate assessments,” said Mattias Karlsson, Chief Executive Officer at Cellectricon. “We recognized that our existing validated assays were exceptionally well suited to address these needs. By building on our trusted assays and in vitro models, we’re proud to offer a robust solution that helps our clients make safer, faster decisions with greater confidence.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics